Skip to main content
. 2009 Mar 25;4(3):e5002. doi: 10.1371/journal.pone.0005002

Table 1. Characteristics of 1,666 persons with HIV infection prescribed primary prophylaxis against Pneumocystis jirovecii pneumonia (PCP), by nonadherence to prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

Characteristics Primary PCP Prophylaxis
Nonadherent* Adherent*
N = 305 N = 1,361
n (%) n (%)
Year of SHAS interview
2000 45 (14.7) 111 (8.2)
2001 82 (26.9) 407 (29.9)
2002 93 (30.5) 411 (30.2)
2003 60 (19.7) 333 (24.5)
2004 25 (8.2) 99 (7.3)
Sex
Male 240 (78.7) 1040 (76.4)
Female 65 (21.3) 321 (23.6)
Race/Ethnicity
White, non-Hispanic 67 (22.0) 273 (20.1)
Black, non-Hispanic 179 (58.7) 762 (56.6)
Hispanic 46 (15.1) 269 (19.8)
Other 13 (4.3) 57 (4.7)
Age group (years)
18–29 38 (12.5) 126 (9.3)
30–39 112 (40.0) 498 (36.6)
40–49 113 (37.0) 550 (40.4)
≥50 32 (10.5) 187 (13.7)
Employed
Yes 92 (30.2) 383 (28.1)
No 213 (69.8) 978 (71.9)
Current annual income
<$10,000 161 (57.8) 666 (48.9)
$10,000–20,000 53 (17.4) 265 (19.5)
≥$20,000 70 (22.9) 322 (23.7)
Unknown or refused to answer 21 (6.9) 108 (7.9)
Education
<High school/General Equivalency Diploma (GED) 94 (30.8) 446 (32.8)
High school/GED 95 (31.1) 433 (31.8)
>High school/GED 116 (38.0) 482 (35.4)
Medical insurance
Yes 240 (78.7) 1,075 (79.0)
No 65 (21.3) 286 (21.0)
Region of residence
Northeast 25 (8.2) 73 (5.4)
South 155 (50.8) 728 (53.5)
Midwest 48 (15.7) 212 (15.6)
West 77 (25.2) 348 (25.6)
Current living situation
Alone 100 (32.8) 403 (29.6)
With partner, family, or friend 172 (56.4) 837 (61.5)
In a medical facility 10 (3.3) 42 (3.1)
In shelter 15 (4.9) 47 (3.4)
Other± 8 (2.6) 32 (2.3)
Illicit drug use in past year§
No 142 (46.6) 899 (66.0)
Marijuana only 54 (17.7) 179 (13.1)
Non-injection drugs other than marijuana 81 (26.6) 233 (17.1)
Injection drug use 28 (9.2) 50 (3.7)
Risk for alcoholism||
Yes 103 (33.8) 328 (24.1)
No 202 (66.2) 1.033 (75.9)
Mental health described as not good ≥1 day during the last month
Yes 232 (76.1) 821 (60.3)
No 73 (23.9) 540 (39.7)
Recent CD4 count (cells/μL)
<200 160 (52.5) 536 (39.4)
≥200 77 (25.2) 393 (28.9)
Unknown/missing 68 (22.3) 432 (31.7)
Viral load (copies/mL)
≤5000 108 (35.4) 525 (38.6)
>5,000 74 (24.3) 240 (17.6)
Unknown/missing 123 (40.3) 596 (43.8)
Current PCP medication prescribed
Trimethoprim-sulfamethoxazole 243 (79.7) 1078 (79.2)
Dapsone 37 (12.1) 169 (12.4)
Other/unknown 25 (8.2) 114 (8.4)
Antiretroviral therapy (ART) in the past month
On ART, always adherent 59 (19.3) 910 (66.9)
On ART, usually adherent 125 (41.0) 194 (14.2)
On ART, sometimes, rarely, or never adherent 59 (19.3) 44 (3.2)
On ART, unknown or missing information about adherence 20 (6.6) 104 (7.6)
Not on ART 42 (13.8) 109 (8.0)
Total number of pills prescribed for daily use
1–3 87 (28.5) 371 (27.3)
4–5 120 (39.3) 515 (37.8)
≥6 98 (32.1) 475 (34.9)
Recruitment type
Facility-based 192 (62.9) 894 (65.7)
Population-based 113 (37.0) 467 (34.3)
*

Column percentages may not total 100% because of rounding.

P-value <0.05 when comparing persons nonadherent with those adherent to PCP prophylaxis.

Regions defined by U.S. Census Bureau; for SHAS sites included in this analysis, Northeast comprises NJ, CT, and PA; South comprises GA, MD, FL, SC, DE, and TX; Midwest comprises IL, KS, MI, and MN; and West comprises AZ, CA, CO, NM, and WA.

±

Other responses included correctional institution, refused to answer, and other responses which did not fit into the listed response categories.

§

Categories are mutually exclusive.

||

Defined as answering yes to at least 2 of the CAGE screening questions and reporting alcohol use in the past year.